Published in Lab Business Week, July 3rd, 2005
"We are pleased with our results for FY'05 but not satisfied. We remain committed to our mission of saving lives, leading in technology and innovation, creating shareholder value and having a winning culture," said Michael R. Minogue, CEO and president of Abiomed.
"We have made significant progress in each of these objectives. With the acquisition of Impella, we are now positioned to become the global leader that recovers, supports, and replaces failing hearts," he said.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.